InsiderSignalSign in

← Insider buys

ANAB

AnaptysBio, Inc. · Healthcare

Insiders sold $9.8M of AnaptysBio, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$9.8MSold, 12 mo

$1.4BMarket cap

ANAB over the last year

No insider buys filed in this year

ANAB after insider buys

3 months after each buy, from the first price a copier could get.

−3.2%Average

−1.7 ptsVs S&P 500

2 of 3Higher

3 buys since 2017 with 3 months of prices.

Every filing

72 insider filings since 2017, newest first

Hollings Renton · Director

$249K−31.3%Oct 2

John P. Schmid · Director

$1.2M−39.0%Apr 1

Daniel Faga · President and CEO

$1.1M−3.0%Mar 27

Eric J Loumeau · General Counsel

$540K−44.0%Feb 13

Magda Marquet · Director

$531K−53.0%Jan 16

Dennis Mulroy · CFO

$112K−10.0%Jan 9

Daniel Faga · President and CEO

$639K−3.0%Jan 9

Paul F. Lizzul · Chief Medical Officer

$163K−8.0%Jan 9

Eric J Loumeau · General Counsel

$99K−15.0%Jan 9

Daniel Faga · President and CEO

$415K−2.0%Jan 8

Dennis Mulroy · CFO

$86K−10.0%Jan 8

Eric J Loumeau · General Counsel

$439K−51.0%Jan 8

Paul F. Lizzul · Chief Medical Officer

$101K−6.0%Jan 8

Daniel Faga · President and CEO

$662K−3.0%Jan 6

Dennis Mulroy · CFO

$145K−19.0%Jan 6

Paul F. Lizzul · Chief Medical Officer

$183K−11.0%Jan 6

Eric J Loumeau · General Counsel

$129K−18.0%Jan 6

Dennis Mulroy · CFO

$500K−52.0%Dec 23

J. Anthony Ware · Director

$193K−29.0%Dec 23

Paul F. Lizzul · Chief Medical Officer

$75K−5.0%Dec 23

Eric J Loumeau · General Counsel

$510K−53.0%Dec 23

Dennis Mulroy · CFO

$705K−63.0%Dec 18

Eric J Loumeau · General Counsel

$1.0M−72.0%Dec 18

Ecor1 Capital, LLC · Director and 10% owner

$1.1M+1.0%Jan 2

Paul F. Lizzul · Chief Medical Officer

$58K−9.0%Sep 24

Dennis Mulroy · CFO

$488K−72.0%Sep 17

Eric J Loumeau · General Counsel

$492K−79.0%Sep 17

Paul F. Lizzul · Chief Medical Officer

$86K−13.0%Sep 17

Paul F. Lizzul · Chief Medical Officer

$80K−15.0%Aug 16

Ecor1 Capital, LLC · 10% owner

$10.0M+4.0%Aug 16

Paul F. Lizzul · Chief Medical Officer

$53K−11.0%Jul 19

Hollings Renton · Director

$306K−84.0%Jul 17

Dennis M Fenton · Director

$45K−50.0%Jun 24

Hollings Renton · Director

$45K−50.0%Jun 18

Dennis Mulroy · CFO

$36K−61.0%May 24

Daniel Faga · CEO

$3.4M−27.0%Mar 26

Eric J Loumeau · General Counsel

$125K−61.0%Feb 21

Dennis Mulroy · CFO

$72K−76.0%Feb 1

Dennis Mulroy · CFO

$48K−35.0%Jan 9

Daniel Faga · CEO

$150K−1.0%Jan 9

Paul F. Lizzul · Chief Medical Officer

$56K−20.0%Jan 9

Eric J Loumeau · General Counsel

$50K−42.0%Jan 9

Dennis Mulroy · CFO

$116K−86.0%Sep 18

Paul F. Lizzul · Chief Medical Officer

$41K−24.0%Sep 18

Eric J Loumeau · General Counsel

$116K−87.0%Sep 18

Eric J Loumeau · COO and General Counsel

$60K−83.0%Jun 10

Ecor1 Capital, LLC · 10% owner

$14.5M+5.0%May 9

Hamza Suria · President and CEO

$1.3M−35.0%Dec 22

Hamza Suria · President and CEO

$713K−23.0%Nov 5

Eric J Loumeau · COO and General Counsel

$175K−100.0%Nov 5

About AnaptysBio, Inc.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.